Help appealing denials for this siRNA therapy for rare severe triglyceride disorders.

Appeal Your Redemplo Denial

Get access to this breakthrough treatment for familial chylomicronemia syndrome.

Understanding Your Redemplo (plozasiran) Denial

Redemplo (plozasiran) is an siRNA therapy approved as an adjunct to diet for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS), an ultra-rare genetic disorder. Patients with FCS have extremely high triglycerides that can cause life-threatening pancreatitis. Insurance denials are common for rare disease medications, but these treatments are medically essential.

Common Reasons for Denial

! FCS diagnosis not genetically confirmed
! Prior authorization required
! Triglyceride levels not documented
! Ultra-high cost orphan drug
! Must try diet therapy first
! Rare disease with limited coverage policies

How We Help

We help you document your FCS diagnosis, genetic testing results, triglyceride levels, history of pancreatitis, and the failure of dietary management alone to control your condition.

Start your Redemplo appeal — it takes about 3 minutes.

Some Types of Evidence We Can Use For Supporting Your Appeal

✓ Plozasiran is an siRNA that targets apolipoprotein C-III (ApoC-III), reducing triglyceride production and lowering the risk of pancreatitis in FCS.

✓ Familial chylomicronemia syndrome is an ultra-rare genetic disorder affecting approximately 1 in 500,000 to 1 million people.

✓ Patients with FCS are at high risk of recurrent acute pancreatitis, which can be life-threatening.

✓ No other approved therapies specifically target FCS, making plozasiran an essential treatment option for these patients.

Patient Assistance & Copay Programs

These programs may help reduce your costs while you appeal:

Rely On REDEMPLO Patient Support

Arrowhead's patient support program offers financial assistance options for eligible patients at each stage of treatment journey.

Eligibility requirements and program terms may change. Please verify current details directly with each organization.

Patient Advocacy & Support Organizations

These organizations provide education, support, and advocacy for patients:

National Organization for Rare Disorders (NORD)

Leading patient advocacy organization for rare disease community.

Global Genes

Leading rare disease patient advocacy organization connecting and empowering patients.

Frequently Asked Questions

FCS is a rare genetic disorder where the body cannot properly break down triglycerides, leading to extremely high levels (often over 1,000 mg/dL) and recurrent episodes of severe pancreatitis.

Key documentation includes genetic testing confirming FCS (mutations in LPL, APOC2, APOA5, LMF1, or GPIHBP1), fasting triglyceride levels, history of pancreatitis episodes, and documentation of adherence to strict dietary fat restriction.

Ready to Fight Your Redemplo (plozasiran) Denial?

Our free AI-powered tool will help you generate a compelling appeal letter in minutes.

Start Your Appeal Chat with AI Assistant

Disclaimer: Fight Health Insurance is not affiliated with, endorsed by, or partnered with any pharmaceutical manufacturer, healthcare provider, medical device company, or patient assistance program, including Arrowhead Pharmaceuticals. All information provided is for educational and informational purposes only and does not constitute medical or legal advice. Please consult with your healthcare provider regarding treatment options and with your insurance company regarding coverage decisions.